Market Research Logo

Surface Protein gp120 - Pipeline Review, H2 2016

Introduction
Global Markets Direct Report Coverage
Surface Protein gp120 Overview
Therapeutics Development
Surface Protein gp120 - Products under Development by Stage of Development
Surface Protein gp120 - Products under Development by Therapy Area
Surface Protein gp120 - Products under Development by Indication
Surface Protein gp120 - Pipeline Products Glance
Late Stage Products
Early Stage Products
Surface Protein gp120 - Products under Development by Companies
Surface Protein gp120 - Products under Development by Universities/Institutes
Surface Protein gp120 - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Surface Protein gp120 - Companies Involved in Therapeutics Development
GlaxoSmithKline Plc
Osel, Inc.
Sanofi Pasteur SA
TeneoBio Inc
United Biomedical, Inc.
ViiV Healthcare Limited
Surface Protein gp120 - Drug Profiles
Abzentek - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AIDSVAX B/B + ALVAC-HIV vCP1521 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMD-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMD-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-585248 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fostemsavir tromethamine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HIV [strains C1086 + TV1] (bivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HIV vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HIV vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HIV vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HIV-1 vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HNG-156 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-48U1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit GP120 for HIV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Gp120 for HIV-1 Infection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Target GP120 and GP41 for HIV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Glycoprotein 120 for HIV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptide to Inhibit gp120 for HIV-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Target gp120 for HIV-1 Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target GP120 and Gp41 for HIV-1 Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VCP-2438 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VRC-01LS - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Surface Protein gp120 - Dormant Projects
Surface Protein gp120 - Discontinued Products
Surface Protein gp120 - Featured News & Press Releases
May 18, 2016: Large-scale HIV vaccine trial to launch in South Africa
Jan 07, 2016: National Institutes of Health Initiates Phase 1 Trial of VRC01LS Anti-HIV Therapeutic Antibody Using Xencor's Xtend Fc Technology
Dec 02, 2015: Abzyme Research Foundation's Inaugural ENDHIV BALL Launches $3 Million Fund for New Therapeutic HIV Vaccine Trial
Jul 21, 2015: Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for Investigational HIV-1 Attachment Inhibitor for Heavily Treatment-Experienced Patients
Jul 08, 2015: Scripps research-designed drug candidate significantly reduces HIV reactivation rate
Feb 25, 2015: 48-Week Analysis of Investigational HIV-1 Attachment Inhibitor Paves Way for Phase III Trial Initiation
Oct 03, 2014: Bristol-Myers Squibb Presents Data of BMS-663068 at IDWeek 2014 Showcasing Continued Innovation in Virology
Jul 30, 2014: Dissolvable fabric loaded with medicine might offer faster protection against HIV
Mar 05, 2014: Bristol-Myers Squibb Presents Promising Phase IIb Data for Novel, Investigational Attachment Inhibitor for HIV-1 Infected Treatment-Experienced Patients
May 06, 2013: Duke Researchers Report Additional Information From Phase III HIV Vaccine Trial In Thailand
Dec 06, 2012: Vaginal microbicide gel may offer a promising strategy for prevention and protection against HIV transmission
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by GlaxoSmithKline Plc, H2 2016
Pipeline by Osel, Inc., H2 2016
Pipeline by Sanofi Pasteur SA, H2 2016
Pipeline by TeneoBio Inc, H2 2016
Pipeline by United Biomedical, Inc., H2 2016
Pipeline by ViiV Healthcare Limited, H2 2016
Dormant Projects, H2 2016
Dormant Projects (Contd..1), H2 2016
Dormant Projects (Contd..2), H2 2016
Discontinued Products, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Surface Protein gp120 - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Surface Protein gp120 - Pipeline Review, H2 2016’, provides in depth analysis on Surface Protein gp120 targeted pipeline therapeutics.

The report provides comprehensive information on the Surface Protein gp120, targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Surface Protein gp120 targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.
  • Updated report will be delivered in 48 hours of order confirmation.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape for Surface Protein gp120
    • The report reviews Surface Protein gp120 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved in Surface Protein gp120 targeted therapeutics and enlists all their major and minor projects
    • The report assesses Surface Protein gp120 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news and deals related to Surface Protein gp120 targeted therapeutics
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand the targeted therapy areas and indications for Surface Protein gp120
    • Identify the use of drugs for target identification and drug repurposing
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Surface Protein gp120 development landscape
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;